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2. 病例纳入标准 ①经Zung氏抑郁自评量表（Zung self-
rating depression scale，SDS）评分＞53和/或Zung氏焦虑自评量
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Abstract: Objective: To explore the superiority of Jiawei Xiaoyao Pills in treating perimenopausal women with 
emotional disorder. Methods: 80 perimenopausal women with emotional disorder screened by SAS and SDS were randomly 
divided into 4 equal groups: Paroxetine group, Livial group, Paroxetine combined with Livial group, Jiawei Xiaoyao Pills group, 
20 in each group. All of them accepted 8 weeks’ therapy. Every patient accepted the assessment of these rating scales (including 
Greene, HAMA, HAMD) one time before and after treatment, and only one test for TESS after treatment. Results: All regimens 
improved the score of Greene and HAMA, and there was no statistical diff erence between diff erent regimens. Except Livial group, 
the other regimens eff ectively improved the score of HAMD (P<0.01). The score of HAMD in Paroxetine combined with Livial 
group and Jiawei Xiaoyao Pills group was increased, better than Paroxetine group (P<0.05), and there was no statistical diff erence 
between Paroxetine combined with Livial group and Jiawei Xiaoyao Pills group (P<0.05). There was no signifi cant diff erence in 
TESS score between the fi rst 3 groups, but they all had a higher score than Jiawei Xiaoyao Pills group, and the diff erences were 
statistically signifi cant (P<0.01). Conclusion: Considering the side eff ects of paroxetine and latent, long-term risk of Livial, the 
regimen of Jiawei Xiaoyao Pills therapy deserved to be advocated in the clinical practice for the disease.
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项目 时间 帕罗西汀组 利维爱组 帕+利组 加味逍遥丸组
Greene 治疗前    26.81±6.37    25.73±5.46    25.44±6.01    27.12±6.42
治疗后      9.35±2.49**      8.74±2.15**      7.26±2.96**      8.31±2.87**
HAMA 治疗前    25.72±5.76    25.43±6.25    25.86±5.49    26.17±6.18
治疗后      4.82±2.54**      5.59±4.07**      4.69±2.31**     3.84±2.46**
HAMD 治疗前    30.34±6.82    30.21±5.17    32.47±7.11    31.82±5.24














































3. 4个治疗组间副反应程度的比较  通过对4个治疗组的副
项目 帕罗西汀组 利维爱组 帕+利组 加味逍遥丸组 F值 P值
Greene总分差    17.46±4.37   16.96±4.21    18.18±4.52   18.81±4.18 1.98 0.10
HAMA总分差   20.90±5.01   19.84±4.76    21.17±4.53   23.33±4.32 2.13 0.09
HAMD总分差    22.19±5.12     6.82±4.11**   28.09±5.24*△△   27.35±5.27*△△ 10.52 0.00
Greene焦虑因子分差     6.54±1.83     5.98±1.79     6.88±1.91      7.01±1.87 2.25 0.08
Greene抑郁因子分差     6.28±1.37      4.14±1.53*      7.97±1.48*△△      7.72±1.33*△△ 7.68 0.00
Greene血管因子分差      0.76±0.15     2.03±0.38**      2.18±0.41**     2.12±0.35** 19.64 0.00
Greene性因子分差      1.85±0.46      4.97±1.16**     5.02±1.09**     4.33±0.94** 17.75 0.00
HAMD睡眠因子分差      4.72±1.21     2.55±0.51**     4.92±1.03△△     4.87±1.06△△ 16.82 0.00
HAMD躯体因子分差      5.89±1.25     4.03±1.17*      6.57±1.32△     6.43±1.26△ 2.77 0.04
表2 4个治疗组间疗效的两两比较（x- ±s，20例）
注：与帕罗西汀组比较，*P<0.05，**P<0.01；与利维爱组比较，△P<0.05，△△P<0.01；与帕+利组比较，▲P<0.05，▲▲P<0.01。下表同。
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帕罗西汀组 利维爱组 帕+利组 加味逍遥丸组 F值 P值
TESS 12.13±3.27 14.54±3.48 14.73±3.48 5.43±0.52**△△▲▲ 19.33 0.00
表3 4个治疗组间副反应程度的比较（x- ±s，20例）
